VosaroxinVosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis. Read from the Chembox of the Wikipedia article Vosaroxin, revision 1341041269.

Property

Value

Formula

C18H19N5O4S, 401.45 g/mol

Boiling point

652 °C

Density

1.5 g/cm³

Flash point

348.1 °C

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.